Rare Disease Cures Accelerator Expected To Drive Lots Of Development – Eventually
You may also be interested in...
Center for Research on Complex Generics will be similar to the Critical Path Institute; training sessions for industry could begin in January.
US FDA is looking for advice on how to design a clinical trial network to complete the third component of its Rare Disease Cures Accelerator Program, but it also wants advice on clinical trial networks more broadly. The rare disease network will need to be global given the more limited patient populations, the agency said.
Agency would receive more than $268m in additional dollars for medical product and food safety as part of substantial FY 2019 increase.